NRC Health and NeoGenomics Post Strong Q2 Earnings

NRC Health (NASDAQ: NRC) reported second‑quarter results that included an 11% year‑over‑year increase in total recurring contract value (TRCV) to $151.9 million and about a 4% rise in revenue. Adjusted EBITDA reached $9.4 million, representing a 27% margin, while a change in revenue‑recognition practices created a $1.5 million headwind for the quarter.

NeoGenomics (NASDAQ: NEO) posted earnings per share of $0.05, beating analyst expectations by $0.02, and generated $201.66 million in revenue, also surpassing forecasts. The company recorded a negative net margin of 13.3% and a negative return on equity of 2.8%, while its stock rose modestly during trading. Insider director Lynn A. Tetrault sold shares valued at about $60 k during the quarter.